Propanorm 150-300mg 50 tabs

$42.00$62.00

Prevention and treatment: ventricular arrhythmias; paroxysmal supraventricular tachyarrhythmias, including paroxysmal atrial flutter / fibrillation and paroxysmal circular tachycardia involving the AV node or additional conduction pathways, if standard therapy is ineffective or contraindicated. 

Free International Shipping

Clear
N/A

Description

Propanorm Composition:
active substance: propafenone hydrochloride;

1 tablet contains propafenone hydrochloride 150mg or 300mg;

Excipients: microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, corn starch, copovidone, magnesium stearate, OPADRY WHITE 02F 28310 (hypromellose, titanium dioxide (E 171), polyethylene glycol), symmetic emulsion.

Indications

Prevention and treatment:

● ventricular arrhythmias;

● paroxysmal supraventricular tachycardias, including paroxysmal form of atrial flutter / fibrillation and paroxysmal tachycardia involving circular

AV-node or additional pathways after failure of standard therapy or contraindication to its implementation.

 

Contraindications

● Hypersensitivity to the active substance or to any component of the Propanorm;

● AV-block II and III level in the absence of a pacemaker;

● right bundle branch block together with the blockade of one of the left bundle branch

● uncontrolled chronic heart failure (left ventricular ejection fraction <35%;

● cardiogenic shock (except arrhythmogenic);

● severe symptomatic sinus bradycardia (heart rate <50 beats / min);

● sick sinus syndrome;

● hypotension (in terms of arterial systolic blood pressure <90 mm Hg);

● hypokalemia, hyperkalemia (potassium necessary correction of the exchange before the treatment);

● severe chronic obstructive pulmonary disease;

● bronchospasm;

● myasthenia gravis;

● severe liver failure;

● renal dysfunction.

Dosage & Administration

Therapy Propanormom recommended starting conditions in the hospital under medical supervision, which has experience in treating arrhythmias. Individual maintenance dose should be determined under cardiological observation conditions, including monitoring of ECG and blood pressure control. If prolonged QRS complex by more than 20%, the dose should be reduced or discontinued until the ECG returns to normal limits.

The drug is used internally by food, the tablets should be swallowed whole without chewing and drinking water.

Additional information

dosage

150mg, 300mg